CD24 and cancer: Bispecific T-cell engagers (BiTEs) that target CD24/Siglec-10 and additional antigens like CD3 may also be a promising immunotherapeutic approach to pursue, since these molecules can also activate CD24-directed T cells to kill cancer cells [71].